Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Post-vaccination T cell immunity to omicron

26 Jul 2022

Abstract excerpt

In late 2021, the omicron variant of SARS Coronavirus 2 (SARS-CoV-2) emerged and replaced the previously dominant delta strain. Effectiveness of COVID-19 vaccines against omicron has been challenging to estimate in clinical studies or is not available for all vaccines or populations of interest. T cell function can be predictive of vaccine longevity and effectiveness against disease, likely in a more robust way...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to Long-Term Effects of COVID-19
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35990661
DOI: 10.3389/fimmu.2022.944713

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Post-vaccination T cell immunity to omicronPMID 35990661Read ↗

Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic reviewSemantic proximity Read ↗

<strong>Efficacy of COVID-19 Vaccines Against the Omicron Variant of SARS-CoV-2</strong>Semantic proximity Read ↗

Vaccines Elicit Highly Cross-Reactive Cellular Immunity to the SARS-CoV-2 Omicron VariantSemantic proximity Read ↗

Facing the Omicron variant – How well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic reviewSemantic proximity Read ↗

Assessment of T-cell Reactivity to the SARS-CoV-2 Omicron Variant by Immunized IndividualsSemantic proximity Read ↗

Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 OmicronSemantic proximity Read ↗

Safety and Cross-Reactive Immune Response Against the Omicron Variant of a Third Dose of CoronaVac, and Immune Persistence of Primary Immunization in Healthy Children and Adolescents: Interim Results from a Double-Blind, Randomised, Placebo-Controlled Phase 2 Clinical TrialSemantic proximity Read ↗

In-depth analysis of T cell immunity and antibody responses in heterologous prime-boost-boost vaccine regimens against SARS-CoV-2 and Omicron variantSemantic proximity Read ↗

SARS-CoV-2 T Cell Responses Elicited by COVID-19 Vaccines or Infection Are Expected to Remain Robust against Omicron.Semantic proximity Read ↗

T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individualsSemantic proximity Read ↗

Breakthrough infections with the omicron and delta variants of SARS-CoV-2 result in similar re-activation of vaccine-induced immunitySemantic proximity Read ↗

Sub‐lineages of the SARS‐CoV‐2 Omicron variants: Characteristics and preventionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.